BridgeBio Pharma

News

BridgeBio gains on phase 3 dwarfism data

Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.

News

BridgeBio two for two as rare disease drug aces ph3 trial

BridgeBio's week just went from great to superb, as it reports a second positive topline result in a pivotal trial of a late-stage pipeline drug.

News

Alnylam joins three-way contest in ATTR cardiomyopathy

Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

News

BridgeBio gets EU nod for ATTR cardiomyopathy drug

BridgeBio and Bayer are poised to challenge Pfizer's Vyndaqel in the EU after acoramidis gets a green light for ATTR cardiomyopathy.

News

BridgeBio poised to challenge Pfizer after Attruby approval

BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer

News

Alnylam hails vutrisiran data, but investors seem sceptical

Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems t

BridgeBio gains on phase 3 dwarfism data

BridgeBio two for two as rare disease drug aces ph3 trial

Alnylam joins three-way contest in ATTR cardiomyopathy

BridgeBio gets EU nod for ATTR cardiomyopathy drug

BridgeBio poised to challenge Pfizer after Attruby approval

Alnylam hails vutrisiran data, but investors seem sceptical

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

BridgeBio Pharma

Editor's Picks